324 related articles for article (PubMed ID: 19481946)
1. Discovery of novel P3 sulfonamide-capped inhibitors of HCV NS3 protease. Inhibitors with improved cellular potencies.
Venkatraman S; Blackman M; Wu W; Nair L; Arasappan A; Padilla A; Bogen S; Bennett F; Chen K; Pichardo J; Tong X; Prongay A; Cheng KC; Girijavallabhan V; George Njoroge F
Bioorg Med Chem; 2009 Jul; 17(13):4486-95. PubMed ID: 19481946
[TBL] [Abstract][Full Text] [Related]
2. Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection.
Venkatraman S; Bogen SL; Arasappan A; Bennett F; Chen K; Jao E; Liu YT; Lovey R; Hendrata S; Huang Y; Pan W; Parekh T; Pinto P; Popov V; Pike R; Ruan S; Santhanam B; Vibulbhan B; Wu W; Yang W; Kong J; Liang X; Wong J; Liu R; Butkiewicz N; Chase R; Hart A; Agrawal S; Ingravallo P; Pichardo J; Kong R; Baroudy B; Malcolm B; Guo Z; Prongay A; Madison V; Broske L; Cui X; Cheng KC; Hsieh Y; Brisson JM; Prelusky D; Korfmacher W; White R; Bogdanowich-Knipp S; Pavlovsky A; Bradley P; Saksena AK; Ganguly A; Piwinski J; Girijavallabhan V; Njoroge FG
J Med Chem; 2006 Oct; 49(20):6074-86. PubMed ID: 17004721
[TBL] [Abstract][Full Text] [Related]
3. Discovery and structure-activity relationship of P1-P3 ketoamide derived macrocyclic inhibitors of hepatitis C virus NS3 protease.
Venkatraman S; Velazquez F; Wu W; Blackman M; Chen KX; Bogen S; Nair L; Tong X; Chase R; Hart A; Agrawal S; Pichardo J; Prongay A; Cheng KC; Girijavallabhan V; Piwinski J; Shih NY; Njoroge FG
J Med Chem; 2009 Jan; 52(2):336-46. PubMed ID: 19102654
[TBL] [Abstract][Full Text] [Related]
4. Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.
Njoroge FG; Chen KX; Shih NY; Piwinski JJ
Acc Chem Res; 2008 Jan; 41(1):50-9. PubMed ID: 18193821
[TBL] [Abstract][Full Text] [Related]
5. Toward second generation hepatitis C virus NS3 serine protease inhibitors: discovery of novel P4 modified analogues with improved potency and pharmacokinetic profile.
Arasappan A; Padilla AI; Jao E; Bennett F; Bogen SL; Chen KX; Pike RE; Sannigrahi M; Soares J; Venkatraman S; Vibulbhan B; Saksena AK; Girijavallabhan V; Tong X; Cheng KC; Njoroge FG
J Med Chem; 2009 May; 52(9):2806-17. PubMed ID: 19371095
[TBL] [Abstract][Full Text] [Related]
6. Discovery of potent sulfonamide P4-capped ketoamide second generation inhibitors of hepatitis C virus NS3 serine protease with favorable pharmacokinetic profiles in preclinical species.
Bogen SL; Arasappan A; Velazquez F; Blackman M; Huelgas R; Pan W; Siegel E; Nair LG; Venkatraman S; Guo Z; Doll R; Shih NY; Njoroge FG
Bioorg Med Chem; 2010 Mar; 18(5):1854-65. PubMed ID: 20149666
[TBL] [Abstract][Full Text] [Related]
7. Second-generation highly potent and selective inhibitors of the hepatitis C virus NS3 serine protease.
Chen KX; Nair L; Vibulbhan B; Yang W; Arasappan A; Bogen SL; Venkatraman S; Bennett F; Pan W; Blackman ML; Padilla AI; Prongay A; Cheng KC; Tong X; Shih NY; Njoroge FG
J Med Chem; 2009 Mar; 52(5):1370-9. PubMed ID: 19196021
[TBL] [Abstract][Full Text] [Related]
8. Toward the back-up of boceprevir (SCH 503034): discovery of new extended P4-capped ketoamide inhibitors of hepatitis C virus NS3 serine protease with improved potency and pharmacokinetic profiles.
Bogen SL; Pan W; Ruan S; Nair LG; Arasappan A; Bennett F; Chen KX; Jao E; Venkatraman S; Vibulbhan B; Liu R; Cheng KC; Guo Z; Tong X; Saksena AK; Girijavallabhan V; Njoroge FG
J Med Chem; 2009 Jun; 52(12):3679-88. PubMed ID: 19456105
[TBL] [Abstract][Full Text] [Related]
9. Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles.
Chen KX; Njoroge FG; Arasappan A; Venkatraman S; Vibulbhan B; Yang W; Parekh TN; Pichardo J; Prongay A; Cheng KC; Butkiewicz N; Yao N; Madison V; Girijavallabhan V
J Med Chem; 2006 Feb; 49(3):995-1005. PubMed ID: 16451065
[TBL] [Abstract][Full Text] [Related]
10. Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus.
Tsantrizos YS
Acc Chem Res; 2008 Oct; 41(10):1252-63. PubMed ID: 18681464
[TBL] [Abstract][Full Text] [Related]
11. Potent aza-peptide derived inhibitors of HCV NS3 protease.
Venkatraman S; Wu W; Shih NY; George Njoroge F
Bioorg Med Chem Lett; 2009 Aug; 19(16):4760-3. PubMed ID: 19596195
[TBL] [Abstract][Full Text] [Related]
12. Potent ketoamide inhibitors of HCV NS3 protease derived from quaternized P1 groups.
Venkatraman S; Velazquez F; Wu W; Blackman M; Madison V; Njoroge FG
Bioorg Med Chem Lett; 2010 Apr; 20(7):2151-5. PubMed ID: 20226659
[TBL] [Abstract][Full Text] [Related]
13. A systematic approach to the optimization of substrate-based inhibitors of the hepatitis C virus NS3 protease: discovery of potent and specific tripeptide inhibitors.
Llinàs-Brunet M; Bailey MD; Ghiro E; Gorys V; Halmos T; Poirier M; Rancourt J; Goudreau N
J Med Chem; 2004 Dec; 47(26):6584-94. PubMed ID: 15588093
[TBL] [Abstract][Full Text] [Related]
14. Potent inhibitors of the hepatitis C virus NS3 protease: use of a novel P2 cyclopentane-derived template.
Johansson PO; Bäck M; Kvarnström I; Jansson K; Vrang L; Hamelink E; Hallberg A; Rosenquist A; Samuelsson B
Bioorg Med Chem; 2006 Aug; 14(15):5136-51. PubMed ID: 16675222
[TBL] [Abstract][Full Text] [Related]
15. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus.
Lamarre D; Anderson PC; Bailey M; Beaulieu P; Bolger G; Bonneau P; Bös M; Cameron DR; Cartier M; Cordingley MG; Faucher AM; Goudreau N; Kawai SH; Kukolj G; Lagacé L; LaPlante SR; Narjes H; Poupart MA; Rancourt J; Sentjens RE; St George R; Simoneau B; Steinmann G; Thibeault D; Tsantrizos YS; Weldon SM; Yong CL; Llinàs-Brunet M
Nature; 2003 Nov; 426(6963):186-9. PubMed ID: 14578911
[TBL] [Abstract][Full Text] [Related]
16. Cyclic sulfones as novel P3-caps for hepatitis C virus NS3/4A (HCV NS3/4A) protease inhibitors: synthesis and evaluation of inhibitors with improved potency and pharmacokinetic profiles.
Velázquez F; Sannigrahi M; Bennett F; Lovey RG; Arasappan A; Bogen S; Nair L; Venkatraman S; Blackman M; Hendrata S; Huang Y; Huelgas R; Pinto P; Cheng KC; Tong X; McPhail AT; Njoroge FG
J Med Chem; 2010 Apr; 53(8):3075-85. PubMed ID: 20302300
[TBL] [Abstract][Full Text] [Related]
17. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
Tsantrizos YS
Biopolymers; 2004; 76(4):309-23. PubMed ID: 15386268
[TBL] [Abstract][Full Text] [Related]
18. Boceprevir, an NS3 protease inhibitor of HCV.
Berman K; Kwo PY
Clin Liver Dis; 2009 Aug; 13(3):429-39. PubMed ID: 19628159
[TBL] [Abstract][Full Text] [Related]
19. Inhibitors of hepatitis C virus NS3.4A protease. Effect of P4 capping groups on inhibitory potency and pharmacokinetics.
Perni RB; Chandorkar G; Cottrell KM; Gates CA; Lin C; Lin K; Luong YP; Maxwell JP; Murcko MA; Pitlik J; Rao G; Schairer WC; Van Drie J; Wei Y
Bioorg Med Chem Lett; 2007 Jun; 17(12):3406-11. PubMed ID: 17482818
[TBL] [Abstract][Full Text] [Related]
20. Phenylglycine as a novel P2 scaffold in hepatitis C virus NS3 protease inhibitors.
Ortqvist P; Peterson SD; Kerblom E; Gossas T; Sabnis YA; Fransson R; Lindeberg G; Helena Danielson U; Karlén A; Sandström A
Bioorg Med Chem; 2007 Feb; 15(3):1448-74. PubMed ID: 17113777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
